You are here

Biomarkers and Diagnostics

Diagnostic, prognostic and predictive biomarkers and diagnostic tools and methods are available for licensing and/or collaborative development.

The Cox-2 Inflammatory Signature is a novel pan-cancer immuno-oncology predictive biomarker with strong proof of concept data on overall patient survival predictions across various malignancies.

Read more

We are seeking a commercial partner interested in pursuing the co-development or licensing of our imaging tracer 18F-FPIA.

Read more

CRUK is seeking a partner to collaborate on a proprietary technology better able to identify mutational patterns in cancer genomes for patient stratification.

Read more

The integrin avß6 is an exciting emerging target for both imaging and therapy across many common tumour types including pancreatic, breast, oesophagus, head and neck, skin, lung and ovarian.

Read more

The Tyrer-Cuzick model has been shown in independent studies to be the most consistently accurate when compared with other available breast cancer risk assessment tools.

Read more